These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38701341)

  • 1. Can incorporating molecular testing improve the accuracy of newborn screening for congenital adrenal hyperplasia?
    Sarafoglou K; Gaviglio A; Wolf C; Lorentz CP; Lteif A; Kyllo J; Radloff G; Detwiler Z; Cuthbert CD; Hodges JS; Grosse SD; Greene CN; Cordovado S
    J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38701341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia.
    Sarafoglou K; Banks K; Gaviglio A; Hietala A; McCann M; Thomas W
    Pediatrics; 2012 Nov; 130(5):e1261-8. PubMed ID: 23071209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Newborn Screening Practices for the Early Detection of Congenital Adrenal Hyperplasia.
    Conlon TA; Hawkes CP; Brady JJ; Loeber JG; Murphy N
    Horm Res Paediatr; 2024; 97(2):113-125. PubMed ID: 37231960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants.
    Sarafoglou K; Gaviglio A; Hietala A; Frogner G; Banks K; McCann M; Thomas W
    J Pediatr; 2014 May; 164(5):1136-40. PubMed ID: 24582106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal 17-hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening.
    Hayashi GY; Carvalho DF; de Miranda MC; Faure C; Vallejos C; Brito VN; Rodrigues AS; Madureira G; Mendonca BB; Bachega TA
    Clin Endocrinol (Oxf); 2017 Apr; 86(4):480-487. PubMed ID: 27978607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
    Stroek K; Ruiter A; van der Linde A; Ackermans M; Bouva MJ; Engel H; Jakobs B; Kemper EA; van den Akker ELT; van Albada ME; Bocca G; Finken MJJ; Hannema SE; Mieke Houdijk ECA; van der Kamp HJ; van Tellingen V; Paul van Trotsenburg AS; Zwaveling-Soonawala N; Bosch AM; de Jonge R; Heijboer AC; Claahsen-van der Grinten HL; Boelen A
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4487-e4496. PubMed ID: 34171085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
    Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
    J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel method to characterize CYP21A2 in Florida patients with congenital adrenal hyperplasia and commercially available cell lines.
    Greene CN; Cordovado SK; Turner DP; Keong LM; Shulman D; Mueller PW
    Mol Genet Metab Rep; 2014; 1():312-323. PubMed ID: 27896104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance.
    Votava F; Novotna D; Kracmar P; Vinohradska H; Stahlova-Hrabincova E; Vrzalova Z; Neumann D; Malikova J; Lebl J; Matern D
    Eur J Pediatr; 2012 Jun; 171(6):935-40. PubMed ID: 22234478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing steroid profiling by liquid chromatography-tandem mass spectrometry improves newborn screening for congenital adrenal hyperplasia in New Zealand.
    de Hora MR; Heather NL; Patel T; Bresnahan LG; Webster D; Hofman PL
    Clin Endocrinol (Oxf); 2021 Jun; 94(6):904-912. PubMed ID: 33471388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele-specific PCR and Next-generation sequencing based genetic screening for Congenital Adrenal Hyperplasia in India.
    Ravichandran L; Korula S; Asha HS; Varghese D; Parthiban R ; Johnson J; Ishwarya J; Shetty S; Cherian KE; Jebasingh F; Kapoor N; Pachat D; Mathai S; Simon A; Rajaratnam S; Paul TV; Thomas N; Chapla A
    Eur J Med Genet; 2021 Dec; 64(12):104369. PubMed ID: 34718183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
    Güran T; Tezel B; Gürbüz F; Selver Eklioğlu B; Hatipoğlu N; Kara C; Şimşek E; Çizmecioğlu FM; Ozon A; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):13-23. PubMed ID: 30111524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of Congenital Adrenal Hyperplasia Using Long-Read Sequencing.
    Liu Y; Chen M; Liu J; Mao A; Teng Y; Yan H; Zhu H; Li Z; Liang D; Wu L
    Clin Chem; 2022 Jul; 68(7):927-939. PubMed ID: 35714169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Birth Weight- or Gestational Age-adjusted Second-tier LCMSMS Cutoffs Improve Newborn Screening for CAH in New Zealand.
    de Hora MR; Heather NL; Webster D; Albert BB; Hofman PL
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3390-e3399. PubMed ID: 34058748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme.
    Lai F; Srinivasan S; Wiley V
    Int J Neonatal Screen; 2020 Sep; 6(3):63. PubMed ID: 33117905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a New Laboratory Protocol for Newborn Screening for Congenital Adrenal Hyperplasia in New Zealand.
    de Hora MR; Heather NL; Webster DR; Albert BB; Hofman PL
    Int J Neonatal Screen; 2022 Oct; 8(4):. PubMed ID: 36278626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping of CYP21A2 for congenital adrenal hyperplasia screening using allele-specific primer extension followed by bead array hybridization.
    Oh Y; Park SW; Chun SM; Lim N; Ahn KS; Ka JO; Jin DK; Han BD
    Mol Diagn Ther; 2009 Dec; 13(6):397-405. PubMed ID: 19925038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of the CYP21A2 gene in dried blood spot samples.
    Marino S; Perez Garrido N; Ramírez P; Pujana M; Dratler G; Belgorosky A; Marino R
    Medicina (B Aires); 2020; 80(3):197-202. PubMed ID: 32442933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: Outcomes of Extended Pilot Study in 241,083 Infants.
    Güran T; Tezel B; Çakır M; Akıncı A; Orbak Z; Keskin M; Selver Eklioğlu B; Ozon A; Özbek MN; Karagüzel G; Hatipoğlu N; Gürbüz F; Çizmecioğlu FM; Kara C; Şimşek E; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2020 Sep; 12(3):287-294. PubMed ID: 32157855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China.
    Zhan X; Han L; Qiu W; Gu X; Guo J; Chang S; Wang Y; Zhang H
    Steroids; 2022 Sep; 185():109056. PubMed ID: 35660382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.